Skip to main content
Download PDF

Volume 21 Supplement 1

Selected Topics in “Systems Biology and Bioinformatics” - 2019: genetics

Genetic polymorphisms of PIP5K2A and course of schizophrenia

BMC Medical Genetics volume 21, Article number: 171 (2020) Cite this article

Abstract

Background

Schizophrenia is a severe highly heritable mental disorder. The clinical heterogeneity of schizophrenia is expressed in the difference in the leading symptoms and course of the disease. Identifying the genetic variants that affect clinical heterogeneity may ultimately reveal the genetic basis of the features of schizophrenia and suggest novel treatment targets. PIP5K2A (Phosphatidylinositol-4-Phosphate 5-Kinase Type II Alpha) has been investigated as a potential susceptibility gene for schizophrenia.

Methods

In this work, we studied the possible association between eleven polymorphic variants of PIP5K2A and the clinical features of schizophrenia in a population of 384 white Siberian patients with schizophrenia. Genotyping was carried out on QuantStudio 5 Real-Time PCR System with a TaqMan Validate SNP Genotyping Assay (Applied Biosystems, USA).

Results

PIP5K2A rs8341 (χ2 = 6.559, p = 0.038) and rs946961 (χ2 = 5.976, p = 0.049) showed significant association with course of schizophrenia (continuous or episodic). The rs8341*CT (OR = 1.63, 95% CI: 1.04–2.54) and rs946961*CC (OR = 5.17, 95% CI: 1.20–22.21) genotypes were associated with a continuous type of course, while the rs8341*TT genotype (OR = 0.53, 95% CI: 0.29–0.97) was associated with an episodic type of course of schizophrenia. Therefore rs8341*TT genotype presumably has protective effect against the more severe continuous course of schizophrenia compared to the episodic one.

Conclusions

Our experimental data confirm that PIP5K2A is a genetic factor influencing the type of course of schizophrenia in Siberian population. Disturbances in the phosphatidylinositol pathways may be a possible reason for the transition to a more severe continuous course of schizophrenia.

Background

Schizophrenia is a severe and persistent mental disorder involving chronic or recurrent psychosis with a population prevalence of nearly 1% [1]. Clinical symptoms of schizophrenia vary among individuals. The results of the major studies on the course of the illness over 20 to 40 years of follow-up are consistent in reporting a chronic, generally persistent course of illness for 50 to 70% of the patients who receive an initial diagnosis of schizophrenia [2,3,4,5,6,7]. The continuous course of schizophrenia is characterized by a worse prognosis than episodic. In Ciompi’s classic study [8] about half of patients with schizophrenia had an undulating course, with partial or full remissions followed by recurrences, in an unpredictable pattern. About one-third had relatively chronic, unremitting course with poor outcome. In that study a minority of patients had a steady pattern of recovery with good outcome. Studies on discharge indicated that about 20% of patients don’t require re-admission, many years after discharge. Among these studies, the Danish one [9] is particularly interesting because the sample size and the long follow-up. Following the first discharge, 20% of the surviving patients had not been readmitted after 10 years of follow-up [10].

It is long known that schizophrenia has a large genetic component, with heritability between 64 and 81% [11, 12]. It is characterized by a substantial genetic heterogeneity with contributions from common, rare, and de novo variants of a large number of genes, in addition to environmental factors. GWAS results indicate that schizophrenia is a polygenic disorder, for which thousands of common genetic variants with modest individual effects act in aggregate to increase disease liability [13,14,15].

Recent research has considerably advanced our understanding in terms of identifying over 100 risk loci associated with schizophrenia. However, many questions remain unanswered, including several which affect their individual clinical significance [16].

It is necessary to investigate the genetic architecture of schizophrenia taking into account not only the presence or absence of a diagnosis of schizophrenia but also the duration, type of the clinical course of disease, leading symptoms (positive or negative) with the main goal of identifying reliable predictive markers as well as new therapeutic targets that might improve the life management of patients with schizophrenia.

PIP5K2A (Phosphatidylinositol-5-Phosphate 4-Kinase, Type II, Alpha) has been investigated as a potential susceptibility gene for schizophrenia [17,18,19,20,21] and antipsychotic induced tardive dyskinesia [22]. The main product of PIP5K2A, PI(4,5) P2, is involved in transmembrane transduction of neurotransmitter signals by regulating functions of numerous neuronal ion channels and transporters [23,24,25]. PIP5K2A upregulates the KCNQ potassium channels [23], the glutamate transporters EAAT3 [24], and glutamate GluA1 receptor [25] via phosphatidylinositol-4,5-bisphosphate (PIP2) synthesis. KCNQ channels suppress basal activity of dopaminergic neurons and dopaminergic firing. EAAT3 transporters take up excessive glutamate from the extracellular space. GluA1 receptors are some of the most important excitatory receptors in the central nervous system. It has been shown that schizophrenia linked mutation (N251S)-PIP5K2A results in reduced function of KCNQ channels, EAAT3 transporters, GluA1 receptors and thereby might explain the loss of dopaminergic, glutamatergic control in patients with schizophrenia carriers of this mutation [23,24,25]. In this work, we studied the possible association between eleven polymorphic variants of PIP5K2A and the clinical characteristics of schizophrenia in a population of Caucasian Siberian patients with schizophrenia in order to establish the possible role of PIP5K2A in the clinical heterogeneity of schizophrenia.

Methods

In this study we examined the contribution of PIP5K2A polymorphisms to the development of the clinical features of schizophrenia, such as the leading symptoms (negative or positive) and the type of course of schizophrenia. Based upon reviewing the literature we selected a set of eleven polymorphisms in PIP5K2A and here we present new data on the association between them and clinical phenotypes in antipsychotic-treated patients with schizophrenia from West Siberia, Russian Federation.

Patients

The work was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013) for experiments involving humans. In this study 384 patients from three psychiatric hospitals in Tomsk, Kemerovo, and Chita oblasts in Siberia were retrieved. The inclusion criteria were a clinical diagnosis of schizophrenia according to ICD-10 (F20), patients aged 18–75 years, Caucasian physical appearance and a signed informed consent form to participate in the study after approval from the study (protocol N63/7.2014) from the Local Bioethics Committee of the Mental Health Research Institute. Exclusion criteria for all patients were non-Caucasian physical appearance (e.g., Mongoloid, Buryats or Khakassians), organic mental disorders (e.g., epilepsy, Parkinson’s disease). Clinical examination and diagnostic assessment were carried out using the Positive and Negative Syndrome Scale (PANSS). The total PANSS score in the group of patients with schizophrenia was 102 [92; 109] (Me [Q1; Q3]). The course of schizophrenia (continuous or episodic) was determined by ICD-10 – in the classification of ICD-10, the fifth character is used for this. Demographic and clinical characteristics of patients with schizophrenia are presented in Table 1.

Table 1 Demographics and clinical characteristics of patients with schizophrenia
Full size table

To study the associations between PIP5K2A polymorphisms and leading symptoms (negative or positive) the total group of 384 patients with schizophrenia was divided into 2 subgroups according to the PANSS survey data: a subgroup of 122 patients with leading negative symptoms and a subgroup of 181 patients with leading positive symptoms. The rest of the patients were not included in the comparison due to the mixed symptoms and the lack of prevalence of positive or negative symptoms according to the PANSS. To study the role of PIP5K2A polymorphisms in the development of the course of schizophrenia the total group of 384 patients with schizophrenia was divided into 2 subgroups: a subgroup of 269 patients with continuous course of schizophrenia and a subgroup of 115 patients with episodic course of the disease.

Blood samples were taken 8 h after overnight fasting in tubes containing EDTA and stored in several aliquots at -20 °C until DNA isolation.

DNA analysis

DNA was isolated from the leukocytes in whole peripheral blood from patients with schizophrenia using the standard phenol-chloroform method. During SNPs selection we were guided by two criteria: a) relevance of selected SNPs to associations with schizophrenia and other mental disorders according to the literature data; b) the minor allele frequency (MAF) of selected SNPs should have been 0.05 (5%) or greater. Information on the selected SNPs for PIP5K2A is presented in Additional file 1. Genotyping of PIP5K2A polymorphisms (rs10828317, rs8341, rs746203, rs10430590, rs946961, rs1132816, rs1417374, rs943190, rs943194, rs1171506, rs11013052) was carried out on QuantStudio 5 Real-Time PCR System with a TaqMan Validate SNP Genotyping Assay (Applied Biosystems, USA). Experimental studies were carried at the core facilities centre of research equipment and experimental biological material “Medical genomics” of Tomsk National Research Medical Center.

Statistical analysis

Statistical analysis was performed using SPSS software for Windows, release 21. The genotypes were checked for Hardy–Weinberg equilibrium using chi-square test. Chi-square test and the Fisher’s exact test, where necessary, were used for between-group comparisons of genotypes or allele frequencies. Pairwise linkage disequilibrium (LD) was computed in Haploview program, version 4.2 [26]. The parameters for LD computation include the correlation coefficient (r2), haplotype estimation using accelerated EM algorithm similar to the partition/ligation method described in Qin et al., 2002 [27].

Results

Association of PIP5K2A polymorphisms with leading (positive vs. negative) symptoms of schizophrenia

The frequency and haplotype analysis found no difference between genotypes and alleles of PIP5K2A polymorphisms in patients with schizophrenia with negative leading symptoms and those with positive leading symptoms (Additional file 2).

Association of PIP5K2A polymorphisms with type of course (continuous vs. episodic) of schizophrenia

From the list of eleven SNPs studied for PIP5K2A rs8341 (χ2 = 6.559, p = 0.038) and rs946961 (χ2 = 5.976, p = 0.049) showed significant association with course of schizophrenia (continuous or episodic). The rs8341*CT (OR = 1.63, 95% CI: 1.04–2.54) and rs946961*CC (OR = 5.17, 95% CI: 1.20–22.21) genotypes were associated with a continuous type of course, while the rs8341*TT genotype (OR = 0.53, 95% CI: 0.29–0.97) was associated with an episodic type of course of schizophrenia (Table 2). Therefore rs8341*TT genotype presumably has protective effect against the more severe continuous course of schizophrenia compared to the episodic one.

Table 2 Frequency distribution of genotypes and alleles of PIP5K2A polymorphisms in patients with schizophrenia with different types of course of the disease
Full size table

We also did PIP5K2A haplotype analysis for these variants in pairs, and a significant difference was observed for several haplotypes (Table 3). After the detected haplotypes were adjusted for multiple comparisons (10,000 permutations), there was no significant difference in the distribution for them.

Table 3 Association of PIP5K2A haplotypes with course of schizophrenia
Full size table

Discussion

Several independent linkage studies using different family samples have suggested that the chromosome region where PIP5K2A locates is schizophrenia susceptible [28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Many neurotransmitter receptors which have been attributed to schizophrenia are connected to the phosphatidylinositol (PI) pathway, and genes involved in the PI pathway are potential candidates for schizophrenia susceptibility. PIP5K2A is an important enzyme in the PI pathway, and is therefore significant for schizophrenia study [19]. PIP5K2A has been shown to be associated with schizophrenia [17,18,19,20,21]. However, the effect of PIP5K2A polymorphisms on the clinical manifestations of the disease has been little investigated. In this study, the course of schizophrenia was studied and attempted to identify associations of genetic polymorphisms of the PIP5K2A with the type of course of schizophrenia and the leading symptoms.

PIP5K2A is located on chromosome 10 (Fig. 1). The length of the region comprising the studied polymorphisms is 303 kb.

Fig. 1
figure 1

Localization of the PIP5K2A gene on chromosome 10

Full size image

Only two of the investigated SNPs in this study are located in the exons; they are 10,828,317 in exon 7 and rs1132816 in exon 1. The rest of the studied SNPs are located in intergenic/non-coding regions. However, these polymorphisms are also important. Several association studies have investigated the relationship between genetic variants at PIP5K2A and schizophrenia. Sewekow et al. (2003) investigated the linkage region on chromosome 10p12 by analyzing 55 densely spaced genetic variants in 71 schizophrenia families of German origin and found two SNPs rs10828317 and rs1417374 to be significantly associated with schizophrenia [43]. A family-based transmission disequilibrium test involving subjects from the German and Israeli populations found that SNPs rs1417374, rs10828317, rs11013052, rs943190, rs10430590, rs746203 and rs8341 in PIP5K2A are significantly associated with schizophrenia [17].

In our work from the list of eleven SNPs studied for PIP5K2A none contributed to the development of leading symptoms (positive or negative) of schizophrenia. We obtained data on the association of two SNPs rs8341 and rs946961 with the type of course of schizophrenia (continuous or episodic). The rs8341*CT and rs946961*CC genotypes were associated with a continuous type of course, while the rs8341*TT genotype was associated with an episodic type of course of schizophrenia. Therefore rs8341*TT genotype presumably has protective effect against the more severe continuous course of schizophrenia compared to the episodic one.

Figure 2 represents the Linkage disequilibrium (LD) plot showing the positions of eleven PIP5K2A polymorphisms in patients with schizophrenia. LD measures were made with the program Haploview version 4.2.

Fig. 2
figure 2

Linkage disequilibrium (LD) pattern for the 11 PIP5K2A variants identified in Russian population of patients with schizophrenia. The plot was generated using Haploview 4.2. Pairwise r2 values are shown in diamonds that represent the pairwise LD between the 2 SNPs at the top left and right of the corresponding diamond. Colour Scheme: White, shades of pink for D’ < 1; bright red for D’ = 1

Full size image

A linkage disequilibrium pattern was performed for 11 SNPs. The highest value of D’ (0,976) and r2 (0.9) was for rs8341 and rs946961 polymorphisms. A haplotype analysis was performed for these SNPs, but we did not reveal any significant associations with the studied clinical characteristics of schizophrenia. In the pairwise analysis of haplotypes, data were obtained on the association of five different haplotypes with the course of schizophrenia. However, after conducting permutation tests, the p level did not reach the significance level. Nevertheless, the data obtained leave open the question about the significance of the polymorphisms included in these haplotypes in the development of the clinical picture of the disease. It is interesting that a synonymous mutation rs1132816 (triplet TST, encoded by serine, is replaced by TCC) is among four of these five haplotypes. Currently, it is believed that synonymous mutations do not affect the function of the protein, since they do not change the amino acid that is encoded by the modified part of the gene. But there is a possibility that such a mutation matters at the stages of transcription or translation of a protein, in any way changing the rate of percentages or the frequency of errors. Nevertheless, it is clear from the data obtained that the rs1132816 polymorphism does not have sufficient power for an independent effect on the course of schizophrenia. Thus, we received confirmation of participation only rs8341 and rs946961 in the development of the schizophrenia clinical phenotypes. PIP5K2A controls the function of neuronal KCNQ potassium channels via phosphatidylinositol-4,5-bisphosphate (PIP2) synthesis [23], which suppress basal activity of dopaminergic neurons and dopaminergic firing. Therefore PIP5K2A modulation of KCNQ potassium channels might influence well dopaminergic neurotransmission in schizophrenia [44]. This regulation could be disrupted in mutant forms of PIP5K2A, which may contribute to the schizophrenia phenotype. Moreover, PIP5K2A is a signaling element in the glutamatergic system regulation, specifically it upregulates glutamate transporter EAAT3 [24], which takes up glutamate from the extracellular space, and glutamate GluA1 receptor [25]. It was shown that functionally impaired kinase like PIP5K2A(N251S) may disturb local PIP2 compositions leading to down regulation of EAAT3 [24], and GluA1 [25] and thus be partially effective through deranged glutamate metabolism in the brain of schizophrenic patients carrying this mutation. We assume that this could at least in theory be true for the studied SNPs. Disturbances of the PI path may be a possible reason for the transition to a more severe continuous course of schizophrenia. However, clarification of its possible role in the etiology of schizophrenia will require further studies.

Conclusions

In conclusion, we found an association of type of course (continuous or episodic) of schizophrenia with PIP5K2A rs8341 and rs946961 that confirms PIP5K2A to be a genetic factor influencing the type of course of schizophrenia in Siberian population. Strength of our study is the relatively large patient population. A relative weakness is understudying of other risk variants of PIP5K2A. Disturbances in the phosphatidylinositol pathways may be a possible reason for the transition to a more severe continuous course of schizophrenia. A further search for genetic markers associated with the development of clinical phenotypes in schizophrenia is needed.

Availability of data and materials

The data generated in current study is available in the public repository by identifier https://doi.org/10.6084/m9.figshare.12525401.

Abbreviations

BDNF:

brain derived neurotrophic factor

CI:

Lower and upper bound 95% confidence intervals

CNP:

2′3’-cyclonucleotide 3′-phosphodiesterase

HWE:

Hardy-Weinberg equilibrium

ICD-10:

International Statistical Classification of Diseases and Related Health Problems 10th Revision

LD:

Linkage disequilibrium

OR:

Odds ratio

PI:

phosphatidylinositol

PIP5K2A:

Phosphatidylinositol-4-Phosphate 5-Kinase Type II Alpha

SNP:

Single nucleotide polymorphism

References

  1. Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 2018;13(4):e0195687. https://doi.org/10.1371/journal.pone.0195687.

  2. DeSisto MJ, Harding CM, McCormick RV, Ashikaga T, Brooks GW. The Maine and Vermont three-decade studies of serious mental illness. I. Matched comparison of cross-sectional outcome. Br J Psychiatry 1995;167:331–338. https://doi.org/10.1192/bjp.167.3.331.

  3. Huber G, Gross G, Schuttler R. A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand 1975;52:49–57. https://doi.org/10.1111/j.1600-0447.1975.tb00022.x.

  4. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991;48: 969–977. https://doi.org/10.1001/archpsyc.1991.01810350009002.

  5. Marneros A, Steinmeyer EM, Deister A, Rohde A, Jünemann H. Long-term outcome of schizoaffective and schizophrenic disorders: a comparative study. III. Social consequences. Eur Arch Psychiatry Neurol Sci. 1989;238:135–9.

    Article  CAS  Google Scholar 

  6. Steinhausen HC, Meier M, Angst J. The Zurich long-term outcome study of child and adolescent psychiatric disorders in males. Psychol Med. 1998;28:375–83.

    Article  CAS  Google Scholar 

  7. Stephens JH, Richard, P, McHugh PR. Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. J Nerv Ment Dis 1997;185:715–721. https://doi.org/10.1097/00005053-199712000-00001.

  8. Ciompi L. The natural history of schizophrenia in the long-term. Br J Psychiatry 1980;136:413–420. https://doi.org/10.1192/bjp.136.5.413.

  9. Bertelsen M, Jeppesen P, Petersen L, et al. Course of illness in a sample of 265 patients with first-episode psychosis―five-year follow- up of the Danish OPUS trial. Schizophr Res 2009;107(2–3): 173–178. https://doi.org/10.1016/j.schres.2008.09.018.

  10. Mura G, Petretto DR, Bhat KM, Carta MG. Schizophrenia: from Epidemiology to Rehabilitation. Clin Pract Epidemiol Ment Health. 2012; 8: 52–66. https://doi.org/10.2174/1745017901208010052.

  11. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234–239. https://doi.org/10.1016/s0140-6736(09)60072-6.

  12. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60(12):1187–1192. https://doi.org/10.1001/archpsyc.60.12.1187.

  13. Psychosis Endophenotypes International Consortium, Wellcome Trust Case-Control Consortium, Bramon E, Pirinen M, Strange A, Lin K, et al. A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry 2014;75(5):386–397. https://doi.org/10.1016/j.biopsych.2013.03.033.

  14. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748–752. https://doi.org/10.1038/nature08185.

  15. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013;45(10): 1150–1159. https://doi.org/10.1038/ng.2742.

  16. Harrison PJ. Recent genetic findings in schizophrenia & their therapeutic relevance. J Psychopharmacol 2015;29(2):85–96. https://doi.org/10.1177/0269881114553647.

  17. Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, Borrmann-Hassenbach M, et al. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 2006;11(9):837–846. https://doi.org/10.1038/sj.mp.4001864.

  18. Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, et al. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 2007;6:113–119. https://doi.org/10.1111/j.1601-183x.2006.00234.x.

  19. He Z, Li Z, Shi Y, Tang W, Huang K, Ma G, et al. The PIP5K2A gene and schizophrenia in the Chinese population--a case-control study. Schizophr Res 2007;94(1–3):359–365. https://doi.org/10.1016/j.schres.2007.04.013.

  20. Saggers-Gray L, Heriani H, Handoko HY, Irmansyah I, Kusumawardhani AA, Widyawati I, et al. Association of PIP5K2A with schizophrenia: a study in an Indonesian family sample. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1310–1313. https://doi.org/10.1002/ajmg.b.30736.

  21. Fedorenko O, Rudikov EV, Gavrilova VA, Boiarko EG, Semke AV, Ivanova SA. Association of (N251S)-PIP5K2A with schizophrenic disorders: a study of the Russian population of Siberia. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113:58–61.

    PubMed  Google Scholar 

  22. Fedorenko OY, Loonen AJ, Lang F, Toshchakova VA, Boyarko EG, Semke AV, et al. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol. 2014;18(6). pii: pyu098. https://doi.org/10.1093/ijnp/pyu098.

  23. Fedorenko O, Strutz-Seebohm N, Henrion U, Ureche ON, Lang F, Seebohm G, et al. A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels. Psychopharmacology 2008;199(1):47–54. https://doi.org/10.17116/jnevro20171175158-61.

  24. Fedorenko O, Tang C, Sopjani M, Föller M, Gehring EM, Strutz-Seebohm N, et al. PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacology 2009;206(3):429–435. https://doi.org/10.1007/s00213-009-1621-5.

  25. Seebohm G, Wrobel E, Pusch M, Dicks M, Terhag J, Matschke V, et al. Structural basis of PI(4,5) P2-dependent regulation of GluA1 by phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP5K2A). Pflugers Arch 2014;466(10):1885–1897. https://doi.org/10.1007/s00424-013-1424-8.

  26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–265. https://doi.org/10.1093/bioinformatics/bth457.

  27. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation- maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71(5):1242–1247. https://doi.org/10.1086/344207.

  28. Rice JP, Goate A, Williams JT, Bierut L, Dorr D, Wu W, et al. Initial genome scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 1, 6, 8, 10, and 12. Am J Med Genet 1997;74(3):247–253. https://doi.org/10.1002/(sici)1096-8628(19970531)74:3<247::aid-ajmg3>3.0.co;2-n.

  29. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, et al. Genome scan of European American schizophrenia pedigrees, results of the NIMH genetics initiative and millennium Consortium. Am J Med Genet 1998;81(4):290–295. https://doi.org/10.1002/(sici)1096-8628(19980710)81:4<290::aid-ajmg3>3.3.co;2-n.

  30. Schwab SG, Hallmayer J, Albus M, Lerer B, Hanses C, Kanyas K, et al. Further evidence for a susceptibility locus on chromosome 10p14–p11 in 72 families with schizophrenia by nonparametric linkage analysis. Am J Med Genet 1998;81(4):302–307. https://doi.org/10.1002/(sici)1096-8628(19980710)81:4<302::aid-ajmg5>3.0.co;2-v.

  31. Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, et al. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Mol Psychiatry 2005(6):638–649. https://doi.org/10.1038/sj.mp.4000791.

  32. Straub RE, MacLean CJ, Martin RB, Ma Y, Myakishev MV, Harris-Kerr C, et al. A schizophrenia locus may be located in region 10p15–p11. Am J Med Genet 1998;81(4):296–301. https://doi.org/10.1002/(sici)1096-8628(19980710)81:4<296::aid-ajmg4>3.0.co;2-s.

  33. Foroud T, Castelluccio PF, Koller DL, Edenberg HJ, Miller M, Bowman E, et al. Suggestive evidence of a locus on chromosome 10p using the NIMH genetics initiative bipolar affective disorder pedigrees. Am J Med Genet 2000;96(1):18–23. https://doi.org/10.1002/(sici)1096-8628(20000207)96:1<18::aid-ajmg6>3.0.co;2-g.

  34. Levinson DF, Holmans P, Straub RE, Owen MJ, Wildenauer DB, Gejman PV, et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. Am J Hum Genet 2000;67(3):652–663. https://doi.org/10.1086/303041.

  35. Maziade, M., Roy MA, Rouillard E, Bissonnette L, Fournier JP, Roy A, et al. A search for specific and common susceptibility loci for schizophrenia and bipolar disorder, a linkage study in 13 target chromosomes. Mol Psychiatry 2001;6(6):684–693. https://doi.org/10.1038/sj.mp.4000915.

  36. DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW, et al. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159(5):803–812. https://doi.org/10.1176/appi.ajp.159.5.803.

  37. KohnY LB. Genetics of schizophrenia: a review of linkage findings. Isr J Psychiatry Relat Sci. 2002;39(4):340–51.

    Google Scholar 

  38. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003;73(1):34–48. https://doi.org/10.1086/376549.

  39. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr, et al. Genome scan metaanalysis of schizophrenia and bipolar disorder, part III, bipolar disorder. Am J Hum Genet 2003;73(1):49–62. https://doi.org/10.1086/376547.

  40. Schumacher J, Kaneva R, Jamra RA, Diaz GO, Ohlraun S, Milanova V, et al. Genomewide scan and fine-mapping linkage studies in four European samples with bipolar affective disorder suggest a new susceptibility locus on chromosome 1p35-p36 and provides further evidence of loci on chromosome 4q31 and 6q24. Am J Hum Genet 2005;77(6):1102–1111. https://doi.org/10.1086/498619.

  41. Holliday E, Mowry B, Chant D, Nyholt D. The importance of modelling heterogeneity in complex disease: application to NIMH schizophrenia genetics initiative data. Hum Genet 2005;117(2–3):160–167. https://doi.org/10.1007/s00439-005-1282-3.

  42. Lambert D, Middle F, Hamshere ML, Segurado R, Raybould R, Corvin A, et al. Stage 2 of the Wellcome Trust UK–Irish bipolar affective disorder sibling–pair genome screen: evidence for linkage on chromosomes 6q16–q21, 4q12–q21, 9p21, 10p14–p12 and 18q22. Mol Psychiatry 2005;10(9):831–841. https://doi.org/10.1038/sj.mp.4001684.

  43. Sewekow CA, Schwab SG, Knapp M, Hallmayer J, Eckstein GN, Gabel S, et al. Association of SNPs with schizophrenia on chromosome 10p, a region with previously detected linkage. Am J Med Genet Part B. 2003;122B:133–4.

    Google Scholar 

  44. Hansen HH, Waroux O, Seutin V, Jentsch TJ, Aznar S, Mikkelsen JD. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol 2008;586(7):1823–1832. https://doi.org/10.1113/jphysiol.2007.149450.

Download references

Acknowledgements

This work was carried out within the framework of Tomsk Polytechnic University Competitiveness Enhancement Program.

About this supplement

This article has been published as part of BMC Medical Genetics Volume 21 Supplement 1, 2020: Selected Topics in “Systems Biology and Bioinformatics” - 2019: medical genetics. The full contents of the supplement are available online at https://bmcmedgenet.biomedcentral.com/articles/supplements/volume-21-supplement-1.

Funding

This work was in part supported by the Russian Foundation for Basic Research, grant # 18–315-20019. The funding bodies played no role in the design of this study and collection, analysis, and interpretation of data and in writing of the manuscript. Publication costs for this article have been funded by authors.

Author information

Author notes

  1. Evgeniya G. Poltavskaya and Olga Yu. Fedorenko contributed equally to this work.

Authors and Affiliations

  1. Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014

    Evgeniya G. Poltavskaya, Olga Yu. Fedorenko, Natalya M. Vyalova, Elena G. Kornetova, Nikolay A. Bokhan & Svetlana A. Ivanova

  2. National Research Tomsk Polytechnic University, Tomsk, Russian Federation

    Olga Yu. Fedorenko & Svetlana A. Ivanova

  3. National Research Tomsk State University, Tomsk, Russian Federation

    Nikolay A. Bokhan

  4. Siberian State Medical University Hospital, Moscowsky Trakt, 2, Tomsk, Russian Federation

    Nikolay A. Bokhan & Svetlana A. Ivanova

  5. Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands

    Anton J. M. Loonen

  6. GGZ Westelijk Noord-Brabant, Hoofdlaan 8, 4661 AA, Halsteren, The Netherlands

    Anton J. M. Loonen

Authors
  1. Evgeniya G. Poltavskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olga Yu. Fedorenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalya M. Vyalova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena G. Kornetova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nikolay A. Bokhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anton J. M. Loonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Svetlana A. Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SI and AL instigated, designed, coordinated, and supervised the study. EP designed and performed the statistical analysis and contributed to writing the paper. OF wrote the study protocol, selected the SNPs, and contributed to writing the paper. EP, NV, EK, and OF monitored the study, collected clinical data, and isolated DNA. EP and NV genotyped the samples and recorded all data in an Excel database. NB and EK supervised the clinical work. EP drafted the manuscript. SI and AL supervised the writing. OF commented on the manuscript. All authors read the paper and agree with its content.

Corresponding author

Correspondence to Evgeniya G. Poltavskaya.

Ethics declarations

Ethics approval and consent to participate

This work was performed in accordance with The Code of Ethics of the World Medical Association for experiments involving humans (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013). All participants gave their signed informed consent to participate, and the study was approved by the Local Bioethics Committee of the Mental Health Research Institute (protocol N63/7.2014).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

Information on the selected SNPs for PIP5K2A.

Additional file 2.

PIP5K2A SNPs in positive vs. negative schizophrenia symptoms.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poltavskaya, E.G., Fedorenko, O.Y., Vyalova, N.M. et al. Genetic polymorphisms of PIP5K2A and course of schizophrenia. BMC Med Genet 21 (Suppl 1), 171 (2020). https://doi.org/10.1186/s12881-020-01107-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12881-020-01107-w

Keywords

BMC Medical Genetics

ISSN: 1471-2350

Contact us